Literature DB >> 14552895

betaII-tubulin and GAP 43 mRNA expression in chronically injured neurons of the red nucleus after a second spinal cord injury.

Paul D Storer1, John D Houle.   

Abstract

Regeneration by chronically injured supraspinal neurons is enhanced by treatment of a spinal cord lesion site with a variety of neurotrophic and growth factors. The removal of scar tissue, with subsequent reinjury of the spinal cord, is necessary for injured axons to access tissue transplants placed into the lesion to support axon regrowth. The present study examined chronically injured and reinjured rubrospinal tract (RST) neurons to determine if changes in gene expression could explain the failure of these neurons to regenerate without exogenous trophic factor support. Adult female rats were subjected to a right full hemisection lesion via aspiration of the cervical level 3 spinal cord. Using radioactive cDNA probes and in situ hybridization, RST neurons in the contralateral red nucleus were examined for changes in mRNA levels of betaII-tubulin and GAP 43 in an acute injury period (6 h-3 days), a chronic injury period (28 days after spinal cord injury (SCI)) and following a second lesion of the chronic injury site (6 h-7 days). Based upon the analysis of gene expression in single cells, GAP-43 mRNA levels were increased as early as 1 day following the initial SCI, but were no different than uninjured control levels at 28 days postoperative (dpo). The response to relesion was more rapid and higher than that detected after the initial injury with a significant increase in GAP 43 mRNA at 6 h that was maintained for at least 7 days. betaII-tubulin mRNA levels remained unchanged until 3 days after an acute injury followed by a decrease in expression to 30% below uninjured control values at 28 dpo. The expression of betaII-tubulin mRNA was significantly higher within 6 h after a second injury, where it remained stable for 5 days before a second increase occurred at 7 days after reinjury of the spinal cord. Thus, neurons in a chronic injury state retain the ability to respond to a traumatic injury and, in fact, neurons subjected to a second injury exhibit a significantly heightened expression of regeneration-associated genes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14552895     DOI: 10.1016/s0014-4886(03)00181-x

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  6 in total

Review 1.  Peripheral nerve grafts support regeneration after spinal cord injury.

Authors:  Marie-Pascale Côté; Arthi A Amin; Veronica J Tom; John D Houle
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

2.  Exogenous BDNF enhances the integration of chronically injured axons that regenerate through a peripheral nerve grafted into a chondroitinase-treated spinal cord injury site.

Authors:  Veronica J Tom; Harra R Sandrow-Feinberg; Kassi Miller; Cheryl Domitrovich; Julien Bouyer; Victoria Zhukareva; Michelle C Klaw; Michel A Lemay; John D Houlé
Journal:  Exp Neurol       Date:  2012-09-27       Impact factor: 5.330

Review 3.  Epigenetic regulation of axon outgrowth and regeneration in CNS injury: the first steps forward.

Authors:  Ricco Lindner; Radhika Puttagunta; Simone Di Giovanni
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 4.  Current Concept of Stem Cell Therapy for Spinal Cord Injury: A Review.

Authors:  Sun Kyu Oh; Sang Ryong Jeon
Journal:  Korean J Neurotrauma       Date:  2016-10-31

5.  Combinatory repair strategy to promote axon regeneration and functional recovery after chronic spinal cord injury.

Authors:  Marc A DePaul; Ching-Yi Lin; Jerry Silver; Yu-Shang Lee
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

6.  Epidural Electrical Stimulation: A Review of Plasticity Mechanisms That Are Hypothesized to Underlie Enhanced Recovery From Spinal Cord Injury With Stimulation.

Authors:  Jaclyn T Eisdorfer; Rupert D Smit; Kathleen M Keefe; Michel A Lemay; George M Smith; Andrew J Spence
Journal:  Front Mol Neurosci       Date:  2020-09-02       Impact factor: 5.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.